Ovid

OVID NASDAQ
2.130
-0.020
-0.93%
交易中 14:28 08/21 EDT
开盘
2.170
昨收
2.150
最高
2.170
最低
2.120
成交量
1.19万
成交均量(3M)
29.14万
52周最高
6.91
52周最低
1.530
换手率
0.03%
市值
8,241.61万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Ovid OVID股票价格,Ovid股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
展开 >

最近浏览

名称
价格
涨跌幅